Select language:  
1800 620 420
Close menu

Unlocking the Mysteries of Blood Cancer

In the ever-evolving landscape of blood cancer research, the quest to combat blood cancer continues to push boundaries. The New Directions in Leukaemia Research (NDLR) event in Adelaide last month brought together leading minds in the field to discuss breakthroughs, challenges, and the future of leukaemia treatment. From cutting-edge advancements in therapies to the promise of personalised medicine, the conference, sponsored by the Leukaemia Foundation, shed light on the latest discoveries and strategies shaping the fight against leukaemia.

  • Research
Read more

Leukaemia Foundation calls for greater awareness of myeloma as incidence rates set to more than double by 2035

With myeloma incidence rates set to more than double by 2035, the Leukaemia Foundation is urgently calling for greater awareness and equitable access to treatment across the country, so myeloma patients have the best chance of survival, no matter where they live.

  • Media releases
  • Research
Read more

Replacing ‘blunt-edged’ chemotherapy with targeted treatment

To save more lives from AML, we urgently need to look past standard chemotherapy toward new, more effective approaches to treatment. Supported by Tour de Cure, one of our inaugural Breakthrough Fellowship recipients, Dr Ashwin Unnikrishnan, is doing just that.

  • Research
Read more
Dr Ashwin Unnikrishnan - Leukaemia Foundation Breakthrough Fellowship Recipient

Uncovering the secrets behind leukaemia treatment resistance

Acute lymphoblastic leukaemia (ALL) is a type of blood cancer, which sees the body produce dangerous numbers of immature white blood cells. Supported by Tour de Cure, one of our inaugural Breakthrough Fellowship recipients, Dr Ashley Ng, is leading advanced research to improve our understanding of treatment-resistant ALL and develop new ways of beating it.

  • Research
Read more
Dr Ashley Ng - Leukaemia Foundation Breakthrough Fellowship Recipient

Giles Purbrick was diagnosed with blood cancer, days after becoming a father

>In January 2020, Giles and wife Jacqui welcomed their baby daughter into the world. But just days later, Giles was hit with a shock blood cancer diagnosis that turned everything on its head.

  • Lifestyle and living well
  • Research
Read more
Giles Purbrick and his wife

AML survivor Sophie Gray shares the role yoga and mindfulness played in her recovery

Sophie was diagnosed with AML in 2019, aged 29. She had a stem cell transplant later the same year from an unrelated donor and has been in remission ever since. After leaning on her yoga and mindfulness practice heavily through her recovery, Sophie underwent her yoga teacher training and teaches in Adelaide. In this article the Leukaemia Foundation asked Sophie some questions about her experience with complementary therapies.

  • Lifestyle and living well
  • Research
Read more
Sophie Gray using Complimentary Therapies

Professor David Joske talks to the Leukaemia Foundation about Complementary therapies

David Joske is a Clinical Haematologist at Sir Charles Gairdner Hospital in Perth Western Australia. He was Head of Department 1994 - 2012 and a Medical Co-Director 2017-2021. In this story David Joske talks to the Leukaemia Foundation about Complementary therapies.

  • Lifestyle and living well
  • Research
Read more
Professor David Joske

Rare brain lymphoma needs more research and clinical trials

Access to clinical trials of novel treatments, including immune checkpoint inhibitors and CAR T-cell therapy, could be a game changer for these patients, according to Dr Colm Keane. He is a clinical haematologist at the Princess Alexandra Hospital in Brisbane and a brain lymphoma researcher at the University of Queensland's Frazer Institute.  

  • Clinical trials
  • Research
Read more
Dr Colm Keane

Improving outcomes for cutaneous T-cell lymphoma and cutaneous graft-versus-host disease

Haematologist, Dr Jessica Elliott’s interest is researching T-cell mediated skin disorders, in particular, two clinically similar but biologically divergent conditions – cutaneous T-cell lymphomas (CTCL) (a subtype of skin lymphoma) and cutaneous graft-versus-host disease (GVHD).

  • Research
Read more
Dr Jessica Elliott

Expert Series: Dr Sun Loo on measurable residual disease in remission and relapse

For Dr Sun Loo, being part of an innovative clinical trial is a perfect fit. It furthers research into her field of interest – measurable residual disease (MRD), and the blood cancer she is passionate about – acute myeloid leukaemia (AML).

  • Interviews with experts
  • Research
Read more
Clinical haematologist and researcher, Dr Sun Loo